C-myc protein expression in B-cell acute lymphoblastic leukemia, prognostic significance?

Leukemia Research

Volumn 38, Issue 9, 2014, Pages 1061-1066

  Allen, Ashleigh ^a   Gill, Kamraan ^a   Hoehn, Daniela ^a   Sulis, Maria ^a   Bhagat, Govind ^a   Alobeid, Bachir ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Acute lymphoblastic leukemia; Adult leukemia; B ALL; C myc; Childhood leukemia; Cytogenetics; Immunohistochemistry; Immunostaining; Prognosis; Protein expression

Indexed keywords

METHOTREXATE; MYC PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER PROGNOSIS; CHILD; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENCE RISK; RISK ASSESSMENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT LEUKEMIA; B-ALL; C-MYC; CHILDHOOD LEUKEMIA; CYTOGENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOSTAINING; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84906934266     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.06.022     Document Type: Article

References (34)

1. Swerdlow S.H., Jaffe E.S. WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours 2008, 439. International Agency for Research on Cancer, Lyon.
2. Carroll W.L. Safety in numbers: hyperdiploidy and prognosis. Blood 2013, 121(13):2374-2376.
3. Ghione F., Gargano D., Guazzelli C., Lippi A. t(1;19) and t(12;17) in childhood acute lymphoblastic leukemia of pre-B type. Cancer Genet Cytogenet 1988, 31:275-278.
4. Johansson B., Moorman A.V., Haas O.A., Watmore A.E., Cheung K.L., Swanton S., et al. Hematologic malignancies with t(4;11)(q21;q23)-a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases, European 11q23 Workshop participants. Leukemia 1998, 12(5):779-787.
5. Bailey L.C., Lange B.J., Rheingold S.R., Bunin N.J. Bone-marrow relapse in paediatric acute lymphoblastic leukaemia. Lancet Oncol 2008, 9(9):873-883.
6. Rowe J.M. Optimal management of adults with ALL. Br J Haematol 2009, 144(4):468-483.
7. Miyawaki Y., Kawachi H., Ooi A., Eishi Y., Kawano T., Inazawa J., et al. Genomic copy-number alterations of MYC and FHIT genes are associated with survival in esophageal squamous-cell carcinoma. Cancer Sci 2012, 103(8):1558-1566.
8. Horiuchi D., Kusdra L., Huskey N.E., Chandriani S., Lenburg M.E., Gonzalez-Angulo A.M., et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012, 209(4):679-696.
9. Tsiatis A.C., Herceg M.E., Keedy V.L., Halpern J.L., Holt G.E., Schwartz H.S., et al. Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma. Mod Pathol 2009, 22(11):1432-1438.
10. Wang Y., Wu M.C., Sham J.S., Zhang W., Wu W.Q., Guan X.Y. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 2002, 95(11):2346-2352.
11. Slack G.W., Gascoyne R.D. MYC and aggressive B-cell lymphomas. Adv Anat Pathol 2011, 18(3):219-228.
12. Dalla-Favera R., Bregni M., Erikson J., Patterson D., Gallo R.C., Croce C.M. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982, 79(24):7824-7827.
13. Johnson N.A., Slack G.W., Savage K.J., Connors J.M., Ben-Neriah S., Rogic S., et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012, 30(28):3452-3459.
14. Smith M., Arthur D., Camitta B., Carroll A.J., Crist W., Gaynon P., et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996, 14(1):18-24.
15. Teachey D.T., Hunger S.P. Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol 2013, 162(5):606-620.
16. Larson R.A., Dodge R.K., Burns C.P., Lee E.J., Stone R.M., Schulman P., et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995, 85(8):2025-2037.
17. Mattano L.A., Devidas M., Nachman J.B., Sather H.N., Hunger S.P., Steinherz P.G., et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol 2012, 13(9):906-915.
18. Silverman L.B., Supko J.G., Stevenson K.E., Woodward C., Vrooman L.M., Neuberg D.S., et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood 2010, 115(7):1351-1353.
19. Vrooman L.M., Stevenson K.E., Supko J.G., O'Brien J., Dahlberg S.E., Asselin B.L., et al. Postinduction dexamethasone and individualized dosing of Escherichia coli l-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study-Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 2013, 31(9):1202-1210.
20. International Standing Committee on Human Cytogenetic Nomenclature, Shaffer L.G., McGowan-Jordan J., Schmid M. ISCN 2013: an international system for human cytogenetic nomenclature (2013) 2013, Karger, Basel.
21. Mitelman ISCN 1995: an international system for human cytogenetic nomenclature (1995): recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Memphis, Tennessee, USA, October 9-13, 1994 1995, 114:1. International Standing Committee on Human Cytogenetic Nomenclature, S. Karger, Basel/New York, [folded leaf of plates].
22. Shaffer L.G., Tommerup N. ISCN 2005: an international system for human cytogenetic nomenclature (2005): recommendations of the International Standing Committee on Human Cytogenetic Nomenclature 2005, International Standing Committee on Human Cytogenetic Nomenclature, Karger, Basel/Farmington, CT, 130 p.
23. International Standing Committee on Human Cytogenetic Nomenclature, et al. ISCN 2009: an international system for human cytogenetic nomenclature (2009) 2009, Karger, Basel/Unionville, CT, vi, 138 p. [1 folded leave].
24. Harrison C.J., Haas O., Harbott J., Biondi A., Stanulla M., Trka J., et al. Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfurt-Munster study group. Br J Haematol 2010, 151(2):132-142.
25. Jeha S., Pei D., Raimondi S.C., Onciu M., Campana D., Cheng C., et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia 2009, 23(8):1406-1409.
26. Lin P., Medeiros L.J. The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma. Curr Hematol Malig Rep 2013, 8(3):243-252.
27. Lundin C., Heldrup J., Ahlgren T., Olofsson T., Johansson B. B-cell precursor t(8;14)(q11;q32)-positive acute lymphoblastic leukemia in children is strongly associated with Down syndrome or with a concomitant Philadelphia chromosome. Eur J Haematol 2009, 82(1):46-53.
28. Kubo Y., Kakazu N., Tasaka T., Oka D., Hirose T., Matsuhashi Y., et al. Acute lymphoblastic leukemia (ALL) with t(8;14)(q11.2;q32) in an elderly patient. Leuk Res 2010, 34(3):e82-e84.
29. Navid F., Mosijczuk A.D., Head D.R., Borowitz M.J., Carroll A.J., Brandt J.M, et al. Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: the Pediatric Oncology Group experience. Leukemia 1999, 13(1):135-141.
30. Moorman A.V., Chilton L., Wilkinson J., Ensor H.M., Bown N., Proctor S.J. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood 2010, 115(2):206-214.
31. Bhagavathi S.A.H. Mechanism of c-myc activation in acute leukemia. Mod Pathol 2014, 27(S2):335.
32. Kluk M.J., Chapuy B., Sinha P., Roy A., Dal Cin P., Neuberg D.S., et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS ONE 2012, 7(4):e33813.
33. Arber J.M., Arber D.A., Jenkins K.A., Battifora H. Effect of decalcification and fixation in paraffin-section immunohistochemistry. Appl Immunohistochem 1996, 4.
34. Miller D.M., Thomas S.D., Islam A., Muench D., Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res 2012, 18(20):5546-5553.